Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04382300 | Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions | unknown | Phase 2 | 39 | Shanghai Chest HospitalOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03006575 | Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04706949 |
| Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment |
| unknown |
| Phase 2 |
| 26 |
| Fudan UniversityOTHER |
| 1 |
| Jan 13, 2021 |
| clinicaltrials |
| NCT04636593 | A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC | unknown | Phase 2 | 43 | First People's Hospital of HangzhouOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04390984 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | unknown | Phase 1 | 22 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04675008 | Central Nervous System(CNS) Efficacy of Dacomitinib | unknown | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT04692935 | Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis | unknown | — | 450 | Jun WangOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT04448379 | Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 | 48 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 28, 2020 | clinicaltrials |
| NCT03803137 | Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection(Onco-VOC) | unknown | N/A | 50 | Hopital FochOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT04669730 | Baduanjin Exercise on Meridian Energy, Lung Function and Heart Rate Variability in Patients Undergoing Lung Operative. | unknown | N/A | 120 | Tzu Chi UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04672759 | A Real-world Study of Durvalumab for Lung Cancer in China | unknown | — | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04667975 | The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy(CKD-702) | unknown | Phase 1 | 74 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT03254004 | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | unknown | Phase 2 | 70 | Samsung Medical CenterOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04654520 | A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLC | unknown | N/A | 290 | Guizhou Medical UniversityOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04393883 | A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC) | unknown | N/A | 216 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT04641754 | A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer | unknown | Phase 2 | 176 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT00410683 | Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery(LUNG ART) | unknown | Phase 3 | 500 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04619537 | A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04619563 | A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients | unknown | Phase 2 | 42 | Shandong Cancer Hospital and InstituteOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT04631146 | Efficacy and Safety of Camrelizumab in Real-World Study | unknown | — | 450 | Guangdong Association of Clinical TrialsOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02977169 | To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03402048 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial(EPIC) | unknown | Phase 3 | 567 | University of Turin, ItalyOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04612673 | A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC | unknown | Phase 2 | 33 | China Medical University, ChinaOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04613804 | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04102982 | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer(MWA in NSCLC) | unknown | Phase 2 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 2, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
| NCT04604470 | Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2(I-SABR2_PDA) | unknown | — | 126 | Maastricht UniversityOTHER | 0 | Oct 27, 2020 | clinicaltrials |
| NCT04575415 | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study(BELLA) | unknown | — | 272 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT04592666 | Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer(APPEAL) | unknown | Phase 2 | 226 | Fudan UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03048500 | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | unknown | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04553887 | Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial(AUTUMN) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03481101 | WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC(WHENII) | unknown | N/A | 60 | Rigshospitalet, DenmarkOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04560244 | A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT04554875 | Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules | unknown | — | 1,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04553601 | Molecular Imaging Visualization of Tumor Heterogeneity in Non-small Cell Lung Cancer | unknown | N/A | 150 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT03502850 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 507 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT04398940 | A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544644 | A Study of Combination Therapy in NSCLC | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Sep 10, 2020 | clinicaltrials |
| NCT04506242 | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 74 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 9, 2020 | clinicaltrials |
| NCT04416035 | A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC(NSCLC) | unknown | Phase 3 | 608 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04530097 | Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC | unknown | N/A | 260 | Shanghai 10th People's HospitalOTHER | 1 | Aug 28, 2020 | clinicaltrials |
| NCT04530708 | Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLC(MARS) | unknown | N/A | 162 | Swedish Lung Cancer Study GroupNETWORK | 1 | Aug 28, 2020 | clinicaltrials |
| NCT03598517 | High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer | unknown | N/A | 50 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT04524299 | Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC | unknown | Phase 2 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04136470 | BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics | unknown | — | 130 | ArdigenINDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04500704 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC(ACROSS1) | unknown | Phase 3 | 166 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500717 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation(ACROSS2) | unknown | Phase 3 | 460 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03267654 | Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | unknown | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jan 28, 2021source: clinicaltrials